中国医学创新2025，Vol.22Issue(29)：1-5,5.DOI:10.3969/j.issn.1674-4985.2025.29.001
局部晚期肾癌术前舒尼替尼新辅助靶向治疗的临床效果
Clinical Efficacy of Neoadjuvant Targeted Therapy with Sunitinib before Surgery for Locally Advanced Renal Carcinoma
景奇 1顾东虎1
作者信息
- 1. 北京大学肿瘤医院内蒙古医院泌尿肿瘤外科 内蒙古 呼和浩特 010020
- 折叠
摘要
Abstract
Objective:To explore the clinical efficacy of neoadjuvant targeted therapy with Sunitinib before surgery for locally advanced renal carcinoma.Method:A total of 112 patients with locally advanced renal carcinoma admitted to Inner Mongolia Hospital of Beijing University Cancer Hospital from July 2020 to June 2023 were selected for the study and randomly divided into observation group and control group,with 56 cases in each group.The control group underwent nephrectomy,while the observation group was given Sunitinib neoadjuvant targeted therapy for 2 cycles and then underwent nephrectomy.The short-term efficacy,clinical indicators,tumor markers and survival rates of the two groups were observed.Result:The disease control rate of the observation group was higher than that of the control group(P<0.05).The surgery time and hospital stay of the observation group were shorter than those of the control group,the intraoperative blood loss was less than that of the control group,and the radical resection rate was higher than that of the control group(P<0.05).After treatment,compared with the control group,the levels of carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),and cytokeratin 19 fragment(CYFRA21-1)in the observation group were significantly lower(P<0.05).The survival rates of the observation group at 6 months and 1 year after the surgery were both higher than those of the control group(P<0.05).Conclusion:Preoperative Sunitinib neoadjuvant targeted therapy for locally advanced renal carcinoma can improve short-term efficacy,improve clinical indicators,reduce tumor marker levels,and increase survival rates.关键词
局部晚期肾癌/舒尼替尼/新辅助靶向治疗Key words
Localized advanced renal carcinoma/Sunitinib/Neoadjuvant targeted therapy引用本文复制引用
景奇,顾东虎..局部晚期肾癌术前舒尼替尼新辅助靶向治疗的临床效果[J].中国医学创新,2025,22(29):1-5,5.
